Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 138-736, Korea.
Int J Hematol. 2013 Feb;97(2):256-62. doi: 10.1007/s12185-013-1267-2. Epub 2013 Jan 26.
High-dose chemotherapy and autologous stem-cell transplantation (HDCT-ASCT) is a standard therapy for patients with relapsed or refractory Hodgkin lymphoma (HL). However, its efficacy in Asian patients has not been well investigated. A retrospective analysis of outcomes in 10 consecutive patients who underwent ASCT for HL in a single Korean centre from August 2005 to September 2010 was conducted. The median age was 34.5 years (range 17-64 years) and seven patients were male. Six patients were of stage III-IV at presentation. B symptoms were present in six patients. International Prognostic Score (IPS) was as follows: IPS = 1 (n = 5), IPS = 2 (n = 1), IPS = 4 (n = 2), and IPS = 5 (n = 2). The analysis included nine patients with relapsed HL and one primary refractory case. Four patients were in second complete response and the others were in partial response after salvage chemotherapy. With a median follow-up duration of 58.0 months, 3-year progression-free survival rate and overall survival rate from ASCT were 40 and 76 %, respectively. The results suggest that the efficacy of high-dose chemotherapy followed by ASCT in Korean patients with refractory or relapsed HL is comparable to that in Western patients.
大剂量化疗和自体造血干细胞移植（HDCT-ASCT）是复发或难治性霍奇金淋巴瘤（HL）患者的标准治疗方法。然而，其在亚洲患者中的疗效尚未得到充分研究。对 2005 年 8 月至 2010 年 9 月在韩国的一个单一中心接受 ASCT 治疗的 10 例 HL 患者的结果进行了回顾性分析。中位年龄为 34.5 岁（范围 17-64 岁），男性 7 例。6 例患者在初诊时处于 III-IV 期。6 例患者有 B 症状。国际预后评分（IPS）如下：IPS=1（n=5）、IPS=2（n=1）、IPS=4（n=2）和 IPS=5（n=2）。分析包括 9 例复发 HL 和 1 例原发性难治性病例。4 例患者在第二次完全缓解后，其余患者在挽救性化疗后部分缓解。中位随访时间为 58.0 个月，ASCT 后的 3 年无进展生存率和总生存率分别为 40%和 76%。结果表明，HDCT 后继以 ASCT 治疗韩国复发或难治性 HL 患者的疗效与西方患者相当。
